Adaptive Biotechnologies Reports Strong Preliminary 2025 Results, Projects Profitability by End of 2026

summarizeSummary

Adaptive Biotechnologies reported strong preliminary 2025 financial results with significant revenue and clonoSEQ volume growth, and expects to achieve positive adjusted EBITDA and free cash flow by the end of 2026.

check_boxKey Events

• Strong Preliminary 2025 Financial Performance

  Reported preliminary total revenue of approximately $277 million for full year 2025, a 55% increase year-over-year, with Q4 revenue up 51% to $72 million.

• Significant clonoSEQ Volume Growth

  clonoSEQ test volumes increased 39% for the full year 2025 to approximately 105,600 tests, with Q4 volumes up 43% to 30,000 tests.

• Path to Profitability in 2026

  Management expects to achieve positive adjusted EBITDA and positive free cash flow for the entire company by the end of 2026, alongside over 30% clinical volume growth.

• Healthy Cash Position

  Ended 2025 with approximately $227 million in cash, cash equivalents, and marketable securities.

auto_awesomeAnalysis

Adaptive Biotechnologies announced robust preliminary financial results for the fourth quarter and full year 2025, demonstrating significant growth in total revenue and clonoSEQ test volumes. The company's Minimal Residual Disease (MRD) segment, driven by clonoSEQ adoption, showed strong momentum. Crucially, management provided an optimistic outlook for 2026, projecting over 30% clinical volume growth and, most notably, achieving positive adjusted EBITDA and free cash flow by the end of the year. This anticipated shift to profitability is a key milestone that could significantly de-risk the investment thesis and attract broader investor interest.